Page 75 - 2019_04-Haematologica-web

AZA or LEN plus AZA in MDS, CMML and low blast AML
abnormalities in 50% (33/66) of patients consistent with published literature.28,29 Of the 4 patients without abnor- malities detectable by NGS, 1 patient had monosomy 7 detectable on SNP-A resulting in 95.4% (63/66) of cases having a detectable molecular aberration. The average
number of SNP-A abnormalities per case was 7 (range 0- 37). Identification of additional SNP-A abnormalities upstaged cytogenetic risk in 24% (16/65) cases (G-banded karyotype not available in one case). SNP-A and mutation- al data are summarized in Table 2.
haematologica | 2019; 104(4)
703
Table 1. Clinical and hematologic characteristics of 160 patients by assigned treatment cohort.
Baseline characteristics
AZA (n=80)
LEN+AZA (n=80)
Total (n=160)
Age years, median (range) Male
Female
69.1 (42.5-85.9) 52 (65)
28 (35)
42 (53)
36 (45)
71.4 (44.1-87.2) 58 (73)
22 (28)
41 (51)
33 (41)
70.7 (42.5-87.2) 110 (68.8) 50 (31.3)
83 (51.9)
69 (43.1)
ECOG 0
1
2 2(3) 6(8) 8(5.0) Diagnosis WHO
RCUD (RA, RN, RT) RARS
RCMD
RAEB-1
1 (1)
0 (0)
1 (0.6)
RAEB-2
MDS-U
MDS isolated del5q- CMML
AML
6 (8) 24 (30) 11 (14) 16 (20) 0 (0) 2 (3) 12 (15) 8 (10)
3 (4) 28 (35) 11 (14) 15 (19) 1 (1) 1 (1) 10 (13) 11 (14)
9 (5.6) 52 (32.5) 22 (13.8) 31 (19.4) 1 (0.6) 3 (1.9) 22 (13.8) 19 (11.9)
IPSS risk group
Low Int-1 Int-2 High
12 (15) 37 (46) 22 (28) 9 (11)
10 (13) 38 (48) 17 (21) 15 (19)
22 (13.8) 75 (46.9) 39 (24.4) 24 (15.0)
IPSS-R risk group Very Low
Low Intermediate High
2 (3) 24 (32) 23 (31) 16 (21) 10 (13) 5
3 (4) 18 (24) 25 (33) 12 (16) 17 (23) 5
5 (3.3) 42 (28.0) 48 (32.0) 28 (18.7) 27 (18.0 10
Very High
missing
Cytogenetics (IPSS-R)
Very Good Good Intermed Poor
1 (1) 55 (73) 11 (15) 3 (4) 5 (7) 10 (13) 5
2 (3) 51 (68) 11 (15) 2 (3) 9 (12) 13 (17) 5
3 (2.0) 106 (70.7) 22 (14.7) 5 (3.3) 14 (9.3) 23 (15.3) 10
Very poor Carrying 5q- missing
Past therapy EPO
3 (4) 2 (3) 0 (0)
0 (0) 2 (3) 1 (1)
3 (1.9) 4 (2.5) 1 (0.6)
GCSF
Low dose cytarabine Baseline cytopenias
Hb (<100g/L) Neutrophils (<1.5x109/L)
57 (71) 47 (59) 42 (53)
53 (66) 37 (46) 48 (60)
110 (68.8) 84 (52.5) 90 (56.3)
Platelet (<100x109/L)
Hb: hemoglobin; ECOG: Eastern Cooperative Oncology Group; Int: intermediate; MDS-(U): myelodysplastic syndrome-(unclassifiable); RA: refractory anemia, RAEB: refractory anemia with excess blasts; RCMD: refractory cytopenia with multilineage dysplasia; RARS: refractory anemia with ringed sideroblasts; RCUD: refractory cytopenia with unilin- eage dysplasia;RN: refractory neutropenia;RT: refractory thrombocytopenia;WHO: World Health Organisation. Median (range) reported and N (%) unless otherwise specified.